Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inspire Investing LLC

Inspire Investing LLC cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 38.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,151 shares of the biopharmaceutical company's stock after selling 27,522 shares during the quarter. Inspire Investing LLC's holdings in Amicus Therapeutics were worth $406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after acquiring an additional 2,856,101 shares during the period. Neo Ivy Capital Management purchased a new stake in Amicus Therapeutics in the third quarter worth about $702,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Amicus Therapeutics by 51.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company's stock worth $2,381,000 after acquiring an additional 75,807 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company's stock valued at $28,486,000 after acquiring an additional 242,672 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Amicus Therapeutics by 163.8% during the third quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company's stock valued at $1,429,000 after purchasing an additional 83,081 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD traded down $0.04 during mid-day trading on Friday, reaching $9.61. The company had a trading volume of 1,887,373 shares, compared to its average volume of 1,811,303. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $14.03. The business's 50-day moving average is $9.63 and its 200-day moving average is $10.51. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 22,901 shares of company stock worth $259,863 in the last three months. Corporate insiders own 2.20% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Monday, January 13th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Finally, Guggenheim boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.88.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.